Radius Health

Explore BINOSTO, an effervescent tablet for oral solution is indicated treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

Radius Health offers expanded access and compassionate use programs for investigational treatments.

Radius Assist is a patient assistance program by Radius Health for eligible individuals.

The page describes Tymlos, a product developed by Radius Health.

Radius Health provides access to comprehensive osteoporosis publications and updates on research and treatment advancements.

Transaction follows three years of accelerated growth and successful operations under B-FLEXION and Patient Square’s ownership.

The page shares the latest news and media coverage about Radius Health.

KING OF PRUSSIA, Pa., March 18, 2026 – Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic

BOSTON, MA/ January 2, 2025 - Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (“Radius” or the “Company”), a specialty

Radius Health offers career opportunities in biopharmaceuticals.

Radius Health commits to responsible pricing for healthcare solutions.

Radius Health promotes transparency in clinical trials by disclosing accurate and complete information.

Radius Health supports medical education and investigator-initiated study grants.

Radius Health highlights the benefits of collaboration in the biopharmaceutical industry.

Radius Health provides a Medical Support Line for inquiries about its biopharmaceutical solutions.

Radius Health is a commercial-stage pharmaceutical company specializing in bone health and related therapeutic areas.

Radius Health outlines its privacy policy to protect personal information.

The page outlines the terms of use for accessing the Radius Health website.

Paratek Pharmaceuticals has combined with Radius Health, integrating the osteoporosis treatment **TYMLOS® (abaloparatide)** into its specialty pharmaceutical portfolio. The move expands Paratek’s commercial platform, which now includes multiple targeted therapies for high-need medical areas. The deal strengthens its position in the differentiated specialty medicines market.

Mar 2026Radius Health, Inc.News article

B-FLEXION Life Sciences acquires the remaining 57% stake in Radius Health, completing full ownership after three years of joint operations with Patient Square. The transaction marks a consolidation phase following accelerated growth under shared management. Radius Health operates in the life sciences sector, though specific details of its business activities remain unstated.

Jan 2026Radius Health, Inc.News article

Radius Pharmaceuticals secures a court victory in a patent infringement case against Orbicular Pharmaceutical Technologies over the osteoporosis treatment **TYMLOS®**. The U.S. District Court for Massachusetts ruled in favor of Radius and co-plaintiff Ipsen Pharma, blocking Orbicular’s proposed generic version of the drug. Radius, a subsidiary of Radius Health, specializes in bone health therapies.

Jul 2025Radius Health, Inc.News article

Radius Pharmaceuticals grants Pharmanovia exclusive rights to commercialize **abaloparatide**, a bone-forming treatment for osteoporosis in postmenopausal women and high-risk men, across **China and select Asia-Pacific territories**. The agreement covers registration and distribution, expanding market access for the drug in the region.

Jan 2025Radius Health, Inc.News article